ALKS - Alkermes plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Alkermes plc

Connaught House
1 Burlington Road
Dublin 4
Ireland
353 1 772 8000
http://www.alkermes.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees2,000

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard F. PopsChairman & CEO2.57M6.43M1962
Dr. Floyd E. BloomCo-Founder & Director85.5kN/A1937
Mr. James M. FratesSr. VP, CFO & Treasurer876.25k2.57M1967
Dr. Elliot W. EhrichExec. VP of R&D1.1M3.3M1959
Ms. Kathryn L. BibersteinFormer Chief Admin. Officer, Chief Compliance Officer, Chief Risk Officer & Exec. VP1.08M1.66M1959
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Corporate Governance

Alkermes plc’s ISS Governance QualityScore as of July 1, 2018 is 3. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 5; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.